A Phase 2 interventional study of RO6889450 and Placebo in Schizophrenia, Schizoaffective Disorder, sponsored by Hoffmann-La Roche. Completed at 40 sites in 4 countries. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2023-10-10.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Schizophrenia by Hoffmann-La Roche — none open to participants now, none under way, none of them phase 3. Schizophrenia · Hoffmann-La Roche.
Among the 19 studies in Schizophrenia by Hoffmann-La Roche, this one is the 9th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2020, is one of 5 in phase 2, and was the 18th registered.
3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.
Browse Schizophrenia studies →None of the 19 studies in Schizophrenia by Hoffmann-La Roche is open now. The open studies under Schizophrenia, anywhere →
Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2020.
This study's enrollment of 287 is above the median of 71 across 2,947 interventional studies indexed under Schizophrenia.
Median enrollment 294 across the 16 interventional studies, 1,431 across the 3 observational. Of the 19 that completed or were terminated, 3 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 19 studies in Schizophrenia by Hoffmann-La Roche, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will investigate the efficacy and safety of RO6889450 as monotherapy in participants experiencing an acute exacerbation of symptoms of schizophrenia or schizoaffective disorder.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Additional inclusion criteria for optional 36-Week Safety Extension Phase
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 150 mg of RO6889450 QD for 4 weeks or 12 weeks or 48 weeks.
Drug: RO6889450
Participants will receive 45 mg of RO6889450 QD for 4 weeks or 12 weeks or 48 weeks.
Drug: RO6889450
Participants will receive oral placebo QD for 4 weeks. Participants from this arm that continue to the extension period will be randomized to either 45 mg or 150 mg QD of RO6889450 for up to an additional 8 weeks or additional 44 weeks (optional 36-Week Safety Extension Phase).
Drug: Placebo
Participants will receive 4 mg of risperidone QD for 4 weeks or 12 weeks or 48 weeks.
Drug: Risperidone
Participants will receive oral RO6889450 QD.
Participants will receive oral placebo QD.
Participants will receive oral risperidone QD.
Mean Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4
The PANSS is a 30-item rating scale that evaluates positive, negative, and other symptoms in patients with schizophrenia. The Positive subscale is a 7-item scale that assesses features in schizophrenia that are not present in a normal mental state. The Negative subscale is a 7-item scale that assesses features absent in schizophrenia but present in those with a normal mental state. Items are rated on a 7-point scale, where 1 = absent and 7 = extreme, for a maximum score of 49 for each scale. The General subscale is a 16-item scale that assesses the overall severity of schizophrenia and the risk of aggression. Items are rated on the same scale, with a minimum score of 16 and a maximum score of 112. Total scores are calculated by adding subscale scores together, for a minimum score of 30 and a maximum score of 210. Higher scores indicate higher severity.
Time frame: Week 4 (Day 28)
Change From Baseline in PANSS Factor Scores at Week 4
PANSS factors are modified groupings of the 30 PANSS items from the original three subscales (positive, negative, and general psychopathology). Each item is rated on a scale of 1 (absent) to 7 (most extreme). The positive symptom factor contains 8 items (score range 8-56); the negative symptom and disorganized thought/cognition factors contain 7 items (score range 7-49); the uncontrolled hostility/excitement, expressive deficit, and anxiety/depression factors contain 4 items (score range 4-28); and the avolition domain contains 3 items (score range 3-21). The negative and positive totals each have a range of 7-49 and the general total has a range of 16-112. Higher scores indicate higher symptom severity.
Time frame: Week 4 (Day 28)
Proportion of Participants With at Least 20% or 50% Improvement From Baseline in the PANSS Total Score
The PANSS is a 30-item rating scale that evaluates positive, negative, and other symptoms in patients with schizophrenia. The Positive subscale is a 7-item scale that assesses features in schizophrenia that are not present in a normal mental state. The Negative subscale is a 7-item scale that assesses features absent in schizophrenia but present in those with a normal mental state. Items are rated on a 7-point scale, where 1 = absent and 7 = extreme, for a maximum score of 49 for each scale. The General subscale is a 16-item scale that assesses the overall severity of schizophrenia and the risk of aggression. Items are rated on the same scale, with a minimum score of 16 and a maximum score of 112. Total scores are calculated by adding subscale scores together, for a minimum score of 30 and a maximum score of 210. Higher scores indicate higher severity.
Time frame: Baseline to Week 12
Change From Baseline in Clinical Global Impression Severity (CGI-S) Scores
The CGI-S measures global severity of illness at a given point in time using a 7-point scale, where 1 = no symptoms and 7 = very severe symptoms.
Time frame: Week 4 (Day 28)
Clinical Global Impression - Improvement (CGI-I) Scores
The CGI-I measures change from the baseline state at subsequent visits using a 7-point scale, where 1 = very much improved and 7 = very much worse.
Time frame: Week 4 (Day 28)
PANSS Total Score at Week 12
The PANSS is a 30-item rating scale that evaluates positive, negative, and other symptoms in patients with schizophrenia. The Positive subscale is a 7-item scale that assesses features in schizophrenia that are not present in a normal mental state. The Negative subscale is a 7-item scale that assesses features absent in schizophrenia but present in those with a normal mental state. Items are rated on a 7-point scale, where 1 = absent and 7 = extreme, for a maximum score of 49 for each scale. The General subscale is a 16-item scale that assesses the overall severity of schizophrenia and the risk of aggression. Items are rated on the same scale, with a minimum score of 16 and a maximum score of 112. Total scores are calculated by adding subscale scores together, for a minimum score of 30 and a maximum score of 210. Higher scores indicate higher severity.
Time frame: Week 12
Proportion of Participants With at Least 20% or 50% Improvement in the PANSS Total Score up to Week 12
The PANSS is a 30-item rating scale that evaluates positive, negative, and other symptoms in patients with schizophrenia. The Positive subscale is a 7-item scale that assesses features in schizophrenia that are not present in a normal mental state. The Negative subscale is a 7-item scale that assesses features absent in schizophrenia but present in those with a normal mental state. Items are rated on a 7-point scale, where 1 = absent and 7 = extreme, for a maximum score of 49 for each scale. The General subscale is a 16-item scale that assesses the overall severity of schizophrenia and the risk of aggression. Items are rated on the same scale, with a minimum score of 16 and a maximum score of 112. Total scores are calculated by adding subscale scores together, for a minimum score of 30 and a maximum score of 210. Higher scores indicate higher severity.
Time frame: Weeks 4, 8, and 12
CGI-S up to Week 12
The CGI-S measures global severity of illness at a given point in time using a 7-point scale, where 1 = no symptoms and 7 = very severe symptoms.
Time frame: Up to Week 12
CGI-I up to Week 12
The CGI-I measures change from the baseline state at subsequent visits using a 7-point scale, where 1 = very much improved and 7 = very much worse.
Time frame: Up to Week 12
Participants Ready for Discharge From First Randomized Treatment Intake to Readiness for Discharge as Assessed by the Readiness for Discharge Questionnaire (RDQ) at 4-Week Treatment
The RDQ is a tool used to assess inpatients with schizophrenia on their readiness for discharge from inpatient treatment. It consists of five items that assess suicidality/homicidality, control of aggression/impulsivity, activities of daily living, medication-taking, and delusions/hallucinations interfering with functioning and global status. An additional item examines the overall clinical state of the patient and the final question assesses readiness for discharge. The values reported are the proportion (expressed as a percentage) of participants in each analysis group considered ready for discharge according to the RDQ.
Time frame: after 4-week treatment
Plasma Concentration of RO6889450
Time frame: Day 7 - Day 336
| Milestone | Placebo | RO6889450 45 mg | RO6889450 150 mg | Risperidone 4 mg | Placebo - RO6889450 45 mg | Placebo - RO6889450 150 mg |
|---|---|---|---|---|---|---|
| Started | 73 | 71 | 69 | 74 | 0 | 0 |
| Completed | 56 | 55 | 53 | 60 | 0 | 0 |
| Not completed | 17 | 16 | 16 | 14 | 0 | 0 |
| Withdrew: Adverse event | 6 | 4 | 5 | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 3 | 3 | 5 | 1 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 7 | 9 | 5 | 12 | 0 | 0 |
| Milestone | Placebo | RO6889450 45 mg | RO6889450 150 mg | Risperidone 4 mg | Placebo - RO6889450 45 mg | Placebo - RO6889450 150 mg |
|---|---|---|---|---|---|---|
| Started | 0 | 44 | 46 | 56 | 25 | 26 |
| Completed | 0 | 30 | 26 | 38 | 9 | 12 |
| Not completed | 0 | 14 | 20 | 18 | 16 | 14 |
| Withdrew: Adverse event | 0 | 1 | 4 | 3 | 1 | 3 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 4 | 4 | 1 | 3 | 3 |
| Withdrew: Lost to follow-up | 0 | 1 | 5 | 2 | 3 | 2 |
| Withdrew: Non-compliance with study drug | 0 | 1 | 0 | 0 | 0 | 1 |
| Withdrew: Other | 0 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 2 | 0 | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 3 | 7 | 11 | 8 | 4 |
The PANSS is a 30-item rating scale that evaluates positive, negative, and other symptoms in patients with schizophrenia. The Positive subscale is a 7-item scale that assesses features in schizophrenia that are not present in a normal mental state. The Negative subscale is a 7-item scale that assesses features absent in schizophrenia but present in those with a normal mental state. Items are rated on a 7-point scale, where 1 = absent and 7 = extreme, for a maximum score of 49 for each scale. The General subscale is a 16-item scale that assesses the overall severity of schizophrenia and the risk of aggression. Items are rated on the same scale, with a minimum score of 16 and a maximum score of 112. Total scores are calculated by adding subscale scores together, for a minimum score of 30 and a maximum score of 210. Higher scores indicate higher severity.
| Units on a scale | Placebo | RO6889450 45 mg | RO6889450 150 mg | Risperidone 4 mg |
|---|---|---|---|---|
| Baseline | 99.38 ± 11.36 | 98.54 ± 9.51 | 100.53 ± 12.25 | 100.03 ± 10.56 |
| Day 28 | 88.69 ± 20.18 | 88.94 ± 17.03 | 85.18 ± 17.67 | 78.04 ± 15.78 |
PANSS factors are modified groupings of the 30 PANSS items from the original three subscales (positive, negative, and general psychopathology). Each item is rated on a scale of 1 (absent) to 7 (most extreme). The positive symptom factor contains 8 items (score range 8-56); the negative symptom and disorganized thought/cognition factors contain 7 items (score range 7-49); the uncontrolled hostility/excitement, expressive deficit, and anxiety/depression factors contain 4 items (score range 4-28); and the avolition domain contains 3 items (score range 3-21). The negative and positive totals each have a range of 7-49 and the general total has a range of 16-112. Higher scores indicate higher symptom severity.
| Units on a scale | Placebo | RO6889450 45 mg | RO6889450 150 mg | Risperidone 4 mg |
|---|---|---|---|---|
| Anxiety/Depression - Baseline | 11.58 ± 3.39 | 12.91 ± 2.92 | 11.54 ± 3.40 | 12.58 ± 3.67 |
| Anxiety/Depression - Day 28 | 9.56 ± 4.03 | 9.88 ± 4.15 | 9.06 ± 4.08 | 8.50 ± 4.09 |
| Avolition - Baseline | 15.99 ± 3.16 | 15.86 ± 2.83 | 16.38 ± 3.25 | 16.20 ± 2.73 |
| Avolition - Day 28 | 14.04 ± 3.70 | 13.67 ± 4.42 | 13.73 ± 3.69 | 12.93 ± 3.44 |
| Disorganized thought/Cognition - Baseline | 21.86 ± 4.43 | 21.43 ± 4.66 | 22.50 ± 4.82 | 21.45 ± 4.87 |
| Disorganized thought/Cognition - Day 28 | 19.69 ± 6.25 | 20.63 ± 4.94 | 19.41 ± 6.44 | 17.07 ± 4.66 |
| Expressive deficit - Baseline | 10.89 ± 3.97 | 10.31 ± 3.96 | 10.90 ± 3.79 | 10.23 ± 3.43 |
| Expressive deficit - Day 28 | 10.81 ± 4.01 | 10.69 ± 4.39 | 10.16 ± 4.18 | 10.71 ± 3.67 |
| Totals general - Baseline | 48.42 ± 6.24 | 48.69 ± 5.49 | 48.68 ± 6.57 | 48.89 ± 6.29 |
| Totals general - Day 28 | 42.43 ± 10.68 | 43.71 ± 9.06 | 40.43 ± 8.94 | 37.07 ± 8.12 |
| Negative symptom factor score - Baseline | 23.58 ± 5.44 | 23.02 ± 5.19 | 23.81 ± 5.36 | 23.34 ± 4.55 |
| Negative symptom factor score - Day 28 | 21.63 ± 6.04 | 21.27 ± 6.63 | 20.80 ± 5.70 | 20.39 ± 5.55 |
| Totals negative - Baseline | 24.10 ± 5.29 | 23.65 ± 4.50 | 24.59 ± 4.87 | 23.65 ± 3.78 |
| Totals negative - Day 28 | 22.65 ± 5.81 | 21.82 ± 5.85 | 22.53 ± 5.41 | 21.45 ± 5.13 |
| Positive symptom factor score - Baseline | 31.40 ± 3.59 | 30.66 ± 3.84 | 32.03 ± 4.89 | 31.15 ± 3.73 |
| Positive symptom factor score - Day 28 | 27.72 ± 7.03 | 28.06 ± 6.14 | 26.63 ± 7.16 | 24.21 ± 5.38 |
| Totals positive - Baseline | 26.86 ± 3.60 | 26.20 ± 4.19 | 27.26 ± 5.13 | 27.49 ± 3.95 |
| Totals positive - Day 28 | 23.61 ± 6.64 | 23.41 ± 6.14 | 22.22 ± 6.50 | 19.52 ± 5.11 |
| Uncontrolled hostility/excitement - Baseline | 10.94 ± 3.94 | 10.52 ± 4.07 | 10.65 ± 4.12 | 11.51 ± 3.90 |
| Uncontrolled hostility/excitement - Day 28 | 10.09 ± 4.83 | 9.10 ± 4.33 | 9.27 ± 4.22 | 7.86 ± 4.06 |
The PANSS is a 30-item rating scale that evaluates positive, negative, and other symptoms in patients with schizophrenia. The Positive subscale is a 7-item scale that assesses features in schizophrenia that are not present in a normal mental state. The Negative subscale is a 7-item scale that assesses features absent in schizophrenia but present in those with a normal mental state. Items are rated on a 7-point scale, where 1 = absent and 7 = extreme, for a maximum score of 49 for each scale. The General subscale is a 16-item scale that assesses the overall severity of schizophrenia and the risk of aggression. Items are rated on the same scale, with a minimum score of 16 and a maximum score of 112. Total scores are calculated by adding subscale scores together, for a minimum score of 30 and a maximum score of 210. Higher scores indicate higher severity.
| Proportion expressed as percentage | Placebo | RO6889450 45 mg | RO6889450 150 mg | Risperidone 4 mg |
|---|---|---|---|---|
| 20% improvement - Week 1 | 18.1 | 26.2 | 27.9 | 25.4 |
| 20% improvement - Week 2 | 26.4 | 24.6 | 36.8 | 43.7 |
| 20% improvement - Week 3 | 31.9 | 32.3 | 38.2 | 59.2 |
| 20% improvement - Week 4 | 30.6 | 32.3 | 36.8 | 59.2 |
| 50% improvement - Week 1 | 0 | 1.5 | 1.5 | 2.8 |
| 50% improvement - Week 2 | 2.8 | 3.1 | 4.4 | 4.2 |
| 50% improvement - Week 3 | 2.8 | 7.7 | 2.9 | 14.1 |
| 50% improvement - Week 4 | 8.3 | 7.7 | 8.8 | 14.1 |
The CGI-S measures global severity of illness at a given point in time using a 7-point scale, where 1 = no symptoms and 7 = very severe symptoms.
| Units on a scale | Placebo | RO6889450 45 mg | RO6889450 150 mg | Risperidone 4 mg |
|---|---|---|---|---|
| Baseline | 5.13 ± 0.50 | 5.09 ± 0.52 | 5.25 ± 0.63 | 5.27 ± 0.61 |
| Day 28 | 4.42 ± 1.07 | 4.35 ± 0.99 | 4.29 ± 0.85 | 3.88 ± 0.94 |
The CGI-I measures change from the baseline state at subsequent visits using a 7-point scale, where 1 = very much improved and 7 = very much worse.
| Units on a scale | Placebo | RO6889450 45 mg | RO6889450 150 mg | Risperidone 4 mg |
|---|---|---|---|---|
| Day 7 | 3.87 ± 0.86 | 3.60 ± 0.76 | 3.56 ± 0.88 | 3.40 ± 0.87 |
| Day 14 | 3.63 ± 0.94 | 3.39 ± 0.95 | 3.33 ± 0.90 | 2.99 ± 1.01 |
| Day 21 | 3.47 ± 1.19 | 3.28 ± 1.06 | 3.13 ± 1.06 | 2.79 ± 1.01 |
| Day 28 | 3.27 ± 1.29 | 3.27 ± 1.17 | 2.96 ± 0.93 | 2.43 ± 0.89 |
The PANSS is a 30-item rating scale that evaluates positive, negative, and other symptoms in patients with schizophrenia. The Positive subscale is a 7-item scale that assesses features in schizophrenia that are not present in a normal mental state. The Negative subscale is a 7-item scale that assesses features absent in schizophrenia but present in those with a normal mental state. Items are rated on a 7-point scale, where 1 = absent and 7 = extreme, for a maximum score of 49 for each scale. The General subscale is a 16-item scale that assesses the overall severity of schizophrenia and the risk of aggression. Items are rated on the same scale, with a minimum score of 16 and a maximum score of 112. Total scores are calculated by adding subscale scores together, for a minimum score of 30 and a maximum score of 210. Higher scores indicate higher severity.
| Units on a scale | Placebo - RO6889450 45 mg | Placebo - RO6889450 150 mg | RO6889450 45 mg | RO6889450 150 mg | Risperidone 4 mg |
|---|---|---|---|---|---|
| Baseline | 103.44 ± 12.58 | 99.12 ± 10.16 | 98.66 ± 9.64 | 99.00 ± 11.37 | 100.30 ± 11.49 |
| Week 12 | 75.10 ± 17.53 | 76.73 ± 21.09 | 76.25 ± 17.89 | 79.30 ± 13.68 | 67.74 ± 11.50 |
The PANSS is a 30-item rating scale that evaluates positive, negative, and other symptoms in patients with schizophrenia. The Positive subscale is a 7-item scale that assesses features in schizophrenia that are not present in a normal mental state. The Negative subscale is a 7-item scale that assesses features absent in schizophrenia but present in those with a normal mental state. Items are rated on a 7-point scale, where 1 = absent and 7 = extreme, for a maximum score of 49 for each scale. The General subscale is a 16-item scale that assesses the overall severity of schizophrenia and the risk of aggression. Items are rated on the same scale, with a minimum score of 16 and a maximum score of 112. Total scores are calculated by adding subscale scores together, for a minimum score of 30 and a maximum score of 210. Higher scores indicate higher severity.
| Proportion expressed as a percentage | Placebo - RO6889450 45 mg | Placebo - RO6889450 150 mg | RO6889450 45 mg | RO6889450 150 mg | Risperidone 4 mg |
|---|---|---|---|---|---|
| Week 4 | 40.0 | 36.0 | 46.3 | 53.3 | 75.5 |
| Week 8 | 36.0 | 28.0 | 43.9 | 37.8 | 69.8 |
| Week 12 | 28.0 | 28.0 | 48.8 | 28.9 | 50.9 |
The CGI-S measures global severity of illness at a given point in time using a 7-point scale, where 1 = no symptoms and 7 = very severe symptoms.
| Units on a scale | Placebo - RO6889450 45 mg | Placebo - RO6889450 150 mg | RO6889450 45 mg | RO6889450 150 mg | Risperidone 4 mg |
|---|---|---|---|---|---|
| Baseline | 5.28 ± 0.54 | 5.16 ± 0.47 | 5.05 ± 0.50 | 5.16 ± 0.60 | 5.26 ± 0.62 |
| Week 12 | 3.33 ± 1.00 | 3.73 ± 1.27 | 3.56 ± 1.01 | 3.90 ± 0.85 | 3.06 ± 0.81 |
The CGI-I measures change from the baseline state at subsequent visits using a 7-point scale, where 1 = very much improved and 7 = very much worse.
| Units on a scale | Placebo - RO6889450 45 mg | Placebo - RO6889450 150 mg | RO6889450 45 mg | RO6889450 150 mg | Risperidone 4 mg |
|---|---|---|---|---|---|
| Day 7 | 3.54 ± 0.66 | 3.76 ± 0.78 | 3.54 ± 0.78 | 3.56 ± 0.84 | 3.38 ± 0.84 |
| Week 12 | 2.33 ± 1.00 | 2.73 ± 1.56 | 2.30 ± 0.91 | 2.65 ± 0.93 | 2.00 ± 0.82 |
The RDQ is a tool used to assess inpatients with schizophrenia on their readiness for discharge from inpatient treatment. It consists of five items that assess suicidality/homicidality, control of aggression/impulsivity, activities of daily living, medication-taking, and delusions/hallucinations interfering with functioning and global status. An additional item examines the overall clinical state of the patient and the final question assesses readiness for discharge. The values reported are the proportion (expressed as a percentage) of participants in each analysis group considered ready for discharge according to the RDQ.
| Percentage of participants | Placebo | RO6889450 45 mg | RO6889450 150 mg | Risperidone 4 mg |
|---|---|---|---|---|
| Participants Ready for Discharge From First Randomized Treatment Intake to Readiness for Discharge as Assessed by the Readiness for Discharge Questionnaire (RDQ) at 4-Week Treatment | 88.9 (79.3 to 95.1) | 83.1 (71.7 to 91.2) | 89.7 (79.9 to 95.8) | 97.2 (90.2 to 99.7) |
| ng/mL | Placebo - RO6889450 45 mg | Placebo - RO6889450 150 mg | RO6889450 45 mg | RO6889450 150 mg |
|---|---|---|---|---|
| Day 7 | — | — | 99.50 ± 69.2 | 423.83 ± 43.2 |
| Day 14 | — | — | 91.53 ± 111.4 | 463.21 ± 73.6 |
| Day 28 | 49.67 ± 155.4 | 212.27 ± 25.0 | 94.57 ± 108.1 | 419.41 ± 93.0 |
| Day 42 | 59.99 ± 248.3 | 274.58 ± 208.8 | 108.57 ± 76.4 | 390.65 ± 138.4 |
| Day 56 | 70.99 ± 320.4 | 217.65 ± 491.6 | 108.59 ± 55.5 | 237.42 ± 541.2 |
| Day 84 | 77.11 ± 85.5 | 165.99 ± 963.0 | 92.24 ± 128.5 | 265.09 ± 353.6 |
| Day 168 | — | — | 95.39 ± 46.0 | 733.98 ± 65.5 |
| Day 336 | — | — | 4.13 ± NA | 139.71 ± 120.6 |
Collected over 4 weeks for double-blind treatment period Up to 48 weeks for extension period. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/72 (0%) | 1/72 (1.4%) | 23/72 (31.9%) |
| RO6889450 45 mg (Double-blind Treatment Period) | 0/65 (0%) | 2/65 (3.1%) | 14/65 (21.5%) |
| RO6889450 150 mg (Double-blind Treatment Period) | 0/68 (0%) | 1/68 (1.5%) | 23/68 (33.8%) |
| Risperidone 4 mg (Double-blind Treatment Period) | 0/71 (0%) | 0/71 (0%) | 36/71 (50.7%) |
| Placebo - RO6889450 45 mg | 0/25 (0%) | 3/25 (12%) | 5/25 (20%) |
| Placebo - RO6889450 150 mg | 1/25 (4%) | 3/25 (12%) | 6/25 (24%) |
| RO6889450 45 mg (Extension Period) | 0/41 (0%) | 1/41 (2.4%) | 7/41 (17.1%) |
| RO6889450 150 mg (Extension Period) | 0/45 (0%) | 6/45 (13.3%) | 12/45 (26.7%) |
| Risperidone 4 mg (Extension Period) | 0/53 (0%) | 1/53 (1.9%) | 5/53 (9.4%) |
| Event | Placebo | RO6889450 45 mg (Double-blind Treatment Period) | RO6889450 150 mg (Double-blind Treatment Period) | Risperidone 4 mg (Double-blind Treatment Period) | Placebo - RO6889450 45 mg | Placebo - RO6889450 150 mg | RO6889450 45 mg (Extension Period) | RO6889450 150 mg (Extension Period) | Risperidone 4 mg (Extension Period) |
|---|---|---|---|---|---|---|---|---|---|
| SchizophreniaPsychiatric disorders | 1/72 | 2/65 | 0/68 | 0/71 | 3/25 | 2/25 | 1/41 | 5/45 | 0/53 |
| Gun shot woundInjury, poisoning and procedural complications | 0/72 | 0/65 | 0/68 | 0/71 | 0/25 | 1/25 | 0/41 | 0/45 | 0/53 |
| AnxietyPsychiatric disorders | 0/72 | 0/65 | 0/68 | 0/71 | 0/25 | 0/25 | 0/41 | 1/45 | 0/53 |
| Suicidal ideationPsychiatric disorders | 0/72 | 0/65 | 0/68 | 0/71 | 0/25 | 0/25 | 0/41 | 0/45 | 1/53 |
| Psychotic disorderPsychiatric disorders | 0/72 | 0/65 | 1/68 | 0/71 | 0/25 | 0/25 | 0/41 | 0/45 | 0/53 |
| Event | Placebo | RO6889450 45 mg (Double-blind Treatment Period) | RO6889450 150 mg (Double-blind Treatment Period) | Risperidone 4 mg (Double-blind Treatment Period) | Placebo - RO6889450 45 mg | Placebo - RO6889450 150 mg | RO6889450 45 mg (Extension Period) | RO6889450 150 mg (Extension Period) | Risperidone 4 mg (Extension Period) |
|---|---|---|---|---|---|---|---|---|---|
| SchizophreniaPsychiatric disorders | 3/72 | 2/65 | 0/68 | 1/71 | 4/25 | 3/25 | 2/41 | 5/45 | 0/53 |
| AgitationPsychiatric disorders | 2/72 | 0/65 | 8/68 | 0/71 | 0/25 | 1/25 | 0/41 | 0/45 | 0/53 |
| Weight increasedInvestigations | 1/72 | 2/65 | 0/68 | 8/71 | 1/25 | 1/25 | 0/41 | 1/45 | 4/53 |
| HeadacheNervous system disorders | 4/72 | 4/65 | 5/68 | 6/71 | 0/25 | 0/25 | 2/41 | 1/45 | 1/53 |
| NauseaGastrointestinal disorders | 4/72 | 0/65 | 2/68 | 6/71 | 0/25 | 1/25 | 1/41 | 2/45 | 0/53 |
| AnxietyPsychiatric disorders | 6/72 | 3/65 | 2/68 | 5/71 | 0/25 | 0/25 | 0/41 | 1/45 | 0/53 |
| InsomniaPsychiatric disorders | 1/72 | 3/65 | 5/68 | 5/71 | 0/25 | 0/25 | 1/41 | 1/45 | 0/53 |
| VomitingGastrointestinal disorders | 2/72 | 0/65 | 1/68 | 5/71 | 0/25 | 0/25 | 1/41 | 1/45 | 0/53 |
The efficacy analysis population (EAP) was used to determine baseline characteristics. The EAP included all randomized participants who received at least one dose of study medication and who had primary efficacy assessments at baseline and on at least one occasion post-baseline.
| Age, Continuous(Years) | Placebo | RO6889450 45 mg | RO6889450 150 mg | Risperidone 4 mg | Total |
|---|---|---|---|---|---|
| Mean | 33.2 ± 7.1 | 34.0 ± 7.0 | 32.3 ± 6.5 | 32.9 ± 7.1 | 33.1 ± 6.9 |
| Sex: Female, Male(Participants) | Placebo | RO6889450 45 mg | RO6889450 150 mg | Risperidone 4 mg | Total |
|---|---|---|---|---|---|
| Female | 19 | 19 | 15 | 18 | 71 |
| Male | 53 | 46 | 53 | 53 | 205 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | RO6889450 45 mg | RO6889450 150 mg | Risperidone 4 mg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 8 | 11 | 8 | 10 | 37 |
| Not Hispanic or Latino | 64 | 54 | 60 | 61 | 239 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | RO6889450 45 mg | RO6889450 150 mg | Risperidone 4 mg | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 0 | 1 |
| Asian | 0 | 1 | 2 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 33 | 27 | 32 | 31 | 123 |
| White | 37 | 35 | 32 | 39 | 143 |
| More than one race | 0 | 1 | 2 | 0 | 3 |
| Unknown or Not Reported | 1 | 1 | 0 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Ran from Sep 2020 to primary completion in Jun 2022, 21 months.
Results were first posted in Oct 2023, 1 year 3 months after primary completion.
Of 57 industry-sponsored phase 2 interventional studies under Schizophrenia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 32. This study's 21 months is close to that.
Counting every sponsor, half of 101 studies reached it within 25 months; a quarter within 15 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ralmitaront